Healthcare services company Astrana Health met Wall Street’s revenue expectations in Q3 2026, with sales up 7.1% year on year to $1.02 billion. On the other hand, next quarter’s revenue guidance of $989 million was less impressive, coming in 3.4% below analysts’ estimates. Its non-GAAP profit of $0.71 per share was 19% below analysts’ consensus estimates.

Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Astrana Health’s third quarter results prompted a negative market reaction, as management pointed to strong organic EBITDA growth and expanding operating margins, driven by improved medical cost performance and operating efficiencies. CEO Brandon Sim emphasized that the company’s platform is enabling scalable growth, citing the maturation of risk-bearing cohorts in Texas and progress in operating leverage. However, attrition in Medicaid and exchange membership, along with modest increases in Medicaid medical cost trends, weighed on the quarter. Sim noted, “The trend is slightly higher than we expected at the beginning of the year, and higher than the overall blended average, 5.2%, which we are coming in under.”

Looking ahead, Astrana Health’s guidance reflects both optimism in Medicare Advantage expansion and caution regarding Medicaid pressures. Management expects mid-teens adjusted EBITDA growth in 2027, driven by the maturation of new cohorts, new Medicare Advantage partnerships, and continued operating leverage. However, CEO Brandon Sim highlighted persistent Medicaid headwinds, stating, “We are expecting a mid to high, or closer to mid EBITDA headwind from Medicaid, net of rate adjustments from both membership attrition as well as potential adverse selection going into 2027.” The company is also planning conservatively for regulatory and membership changes in Medicaid, while investing in Care Enablement and technology-driven efficiencies.

Key insights from management’s remarks

Management credited organic EBITDA growth to improved medical cost control, expansion in full-risk contracts, and efficiency gains from its technology platform, while flagging Medicaid attrition and higher acuity as ongoing challenges.

• Texas cohort maturation: The transition of Medicare Advantage members in Texas from gain share to global risk outperformed expectations, with local physicians leveraging Astrana’s care model to improve profitability and medical cost trends.
• Care Enablement business expansion: The company signed new clients for its AI-powered Care Enablement platform, including a multi-specialty group in Connecticut and a hospital in California, highlighting growing external demand for Astrana’s technology without significant sales investment.
• Full-risk contract growth: Management reported that 82% of capitation revenue is expected under full-risk arrangements by year-end, up from 76% the previous year, supporting greater operating leverage and margin stability.
• Medicaid attrition and acuity: Despite overall medical cost trends tracking below expectations, Medicaid populations experienced higher attrition and adverse selection, with remaining members showing increased risk profiles, prompting management to plan for a 10%-15% decline in Medicaid membership next year.
• Prospect integration complete: The integration of Prospect is now considered part of Astrana’s core business, with greater than 99% provider retention and cost synergies at the high end of management’s target, contributing to operating leverage.

Drivers of future performance

Astrana Health’s outlook is shaped by ongoing Medicare Advantage growth, technology-driven efficiencies, and persistent Medicaid headwinds that could affect profitability in the coming year.

• Medicare Advantage expansion: Management expects further growth from Medicare Advantage through new payer partnerships and higher enrollment in four-star plans, projecting stable margins as rate increases align with medical cost trends.
• Persistent Medicaid headwinds: The company anticipates a mid-to-high single-digit EBITDA headwind in 2027 from Medicaid, reflecting ongoing membership attrition, regulatory changes, and adverse selection among remaining members.
• Technology and Care Enablement investments: Continued investment in the Care Enablement segment and AI-powered operational efficiencies are expected to drive long-term margin expansion, even as management remains cautious about the pace of external client adoption and potential regulatory shifts.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) the pace and scale of new Medicare Advantage partnerships and their impact on margins, (2) further adoption of the Care Enablement platform by external clients, and (3) the degree of Medicaid attrition and whether recent policy changes can mitigate adverse selection. Execution on integrating technology-driven efficiencies and sustaining provider retention will also be important markers for long-term growth.

Astrana Health currently trades at $38, down from $39.01 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Stocks that trumped tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.